Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2018-06-27T01:57:57Z | - |
dc.date.available | 2018-06-27T01:57:57Z | - |
dc.date.issued | 2017-07 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF PHARMACEUTICS, v. 527, No. 1-2, Page. 61-71 | en_US |
dc.identifier.issn | 0378-5173 | - |
dc.identifier.issn | 1873-3476 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0378517317304465 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/72234 | - |
dc.description.abstract | Trastuzumab is a therapeutic monoclonal antibody that selectively recognizes HER2/neu receptor for targeting breast cancers. In this study, we aimed to present a strategy to combine chemo and phototherapy and targeted delivery via monoclonal antibody for enhanced anticancer effects. We co-loaded a chemotherapeutic agent, rapamycin, and a photosensitizer, polypyrrole, in trastuzumab-conjugated liposomes (LRPmAb) for combined chemo-photothermal therapy. LRPmAb had small size (172.2 +/- 9.6 nm), narrow distribution, and negative zeta-potential (-12.0 +/- 0.3 mV). In addition, LRPmAb showed pH- and temperature-dependent release profiles. LRPmAb showed significantly enhanced uptake in BT-474 cells, a natural HER2/neu expressing cell line. We found that these LRPmAb were effective in delivering rapamycin and showed higher therapeutic efficacy in breast cancer cells overexpressing HER2/neu receptors compared with cells that did not overexpress these receptors. Furthermore, LRPmAb showed synergistic activity against rapamycin-sensitive and resistant cell lines in vitro. These findings indicated that LRPmAb-mediated drug delivery could improve the therapeutic efficacy against breast cancer and overcome drug resistance. (C) 2017 Elsevier B.V. All rights reserved. | en_US |
dc.description.sponsorship | This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015R1A2A2A01004118, 2015R1A2A2A04004806). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER SCIENCE BV | en_US |
dc.subject | Targeted nanoparticle | en_US |
dc.subject | Polypyrrole | en_US |
dc.subject | Rapamycin | en_US |
dc.subject | Trastuzumab | en_US |
dc.subject | Breast cancer | en_US |
dc.title | Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy | en_US |
dc.type | Article | en_US |
dc.relation.volume | 527 | - |
dc.identifier.doi | 10.1016/j.ijpharm.2017.05.034 | - |
dc.relation.page | 61-71 | - |
dc.relation.journal | INTERNATIONAL JOURNAL OF PHARMACEUTICS | - |
dc.contributor.googleauthor | Nguyen, Hanh Thuy | - |
dc.contributor.googleauthor | Tran, Tuan Hiep | - |
dc.contributor.googleauthor | Thapa, Raj Kumar | - |
dc.contributor.googleauthor | Phung, Cao Dai | - |
dc.contributor.googleauthor | Shin, Beom Soo | - |
dc.contributor.googleauthor | Jeong, Jee-Heon | - |
dc.contributor.googleauthor | Choi, Han-Gon | - |
dc.contributor.googleauthor | Yong, Chul Soon | - |
dc.contributor.googleauthor | Kim, Jong Oh | - |
dc.relation.code | 2017002781 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.